HOME >> MEDICINE >> NEWS
GlaxoSmithKline's Havrix now approved for use in children aged 12 months and older

Philadelphia, PA October 18, 2005 GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) approved the expanded use of Havrix(R) (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix and may help to further reduce the incidence of hepatitis A in the United States, particularly among young children who often transmit the disease.

"The expanded indication of Havrix marks an important milestone in the fight against hepatitis A in the United States," said William P. Hitchcock, M.D., of the American Board of Pediatrics, La Jolla, California. "Immunizing children under age two helps protect a very vulnerable population that often does not show symptoms of the disease but frequently spreads it to other children and family members."

Havrix for the Prevention of Hepatitis A in Children Aged 12 Months and Older
The FDA approved the expanded use of Havrix in children to 12 months and older on the basis of a pivotal trial which studied the administration of Havrix in children in the United States and Australia. The prospective, open, comparative, multi-center clinical trial involved over 1,000 healthy children and showed Havrix given to children down to the age of 11 months to be comparable to Havrix given to children approximately two years of age with regard to safety and immunogenicity. The study also showed that Havrix can be given concomitantly with OMNIHIBTM [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)], also called Hib conjugate vaccine (PRP-T).

Each subject was enrolled in one of five groups according to their age and previous vaccination history and vaccinated with either Havrix alone or Havrix with Infanrix (D
'"/>


18-Oct-2005


Page: 1 2 3

Related medicine news :

1. Did drug reps encourage doctors to prescribe gabapentin for nonapproved uses?
2. NIH scientists honored for FDA-approved cervical cancer vaccine breakthrough
3. Previously approved drugs may be helpful in fatal pediatric disorder
4. Shires DAYTRANA(TM) transdermal patch approved by FDA for treatment of ADHD
5. Higher dose formulation of FOSRENOL approved to reduce serum phosphorus in esrd patients
6. FDA approved ROZEREM (ramelteon)
7. Cedars-Sinais live donor liver transplant program receives unos-approved designation
8. Many drugs prescribed for chronic insomnia are not approved for that purpose
9. Sildenafil (Viagra) approved for treatment of pulmonary arterial hypertension (PAH) as Revatio
10. Chinese children with hearing devices benefit from new speech test
11. Seat belt injuries could signal more serious trauma in children

Post Your Comments:
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... mental wellness, as well as a number of specific ... integrative care, stigma reduction and mental health in the ... speak about mental health. The campaign also brings special ... inspiring those individuals to speak up and seek help ...
(Date:5/29/2015)... May 29, 2015 Oaksterdam University, the first cannabis ... time to host its popular and highly demanded Basic ... 15 from 10:00 am to 5:30 pm each day. Certification is ... Fair will be held on June 14 from 12:00 pm ... be held at the Plaza Hotel & Casino in downtown Las ...
(Date:5/29/2015)... Mirada, CA (PRWEB) May 29, 2015 ... traumatic brain injuries with the help of their licensed ... mild traumatic brain injuries can lead to an extensive ... impairments; these effects can arise at any time after ... can be caused by any bump or jolt to ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
(Date:5/29/2015)... 29, 2015 The popular all-natural supplement ... rewards based L-Style Select Program that gives bonuses to ... limited to only 100 members per year, lucky members ... on one with fitness experts at Nuretix Research, and ... them provided that they attain and maintain their weight ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 3Health News:Healthpointe’s Los Angeles County Clinics Are Now Offering Treatment for Mild Traumatic Brain Injuries 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
(Date:5/29/2015)... May 29, 2015 Amgen (NASDAQ: ... pivotal Phase 3, global, randomized, placebo-controlled trials evaluating ... of secondary hyperparathyroidism (SHPT) in patients with chronic ... the primary endpoint, demonstrating that a greater proportion ... a greater than 30 percent reduction in parathyroid ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
Cached News: